^ abcGRCh38: Ensembl release 89: ENSG00000151914 - Ensembl, May 2017
^"Human PubMed Reference:".
^Roper K, Gregory SL, Brown NH (Oct 2001). “The plakin family”. J Cell Sci114(Pt 19): 3409-3410. PMID 11682600. http://jcs.biologists.org/content/114/19/3409.long.
^Leung CL, Liem RK, Parry DA, Green KJ (Nov 2002). “The `Spectraplakins': cytoskeletal giants with characteristics of both spectrin and plakin families”. J Cell Sci115(Pt 22): 4215-4225. PMID 12376554. http://jcs.biologists.org/content/115/22/4215.long.
^LEVER WF (1953). “Pemphigus”. Medicine (Baltimore)32 (1): 1-123. PMID 13024494.
^Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WL, Lever WF (May 1967). “Basement zone antibodies in bullous pemphigoid”. JAMA200 (9): 751-756. PMID 4164640.
^Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. (Feb 1986). “Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting”. J Immunol136 (4): 1231-1235. PMID 2418109.
^Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D (January 1989). “Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies”. J Clin Invest82 (6): 1864-1870. doi:10.1172/JCI113803. PMC: 442765. PMID 2461961. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442765/.
^Sawamura D, Nomura K, Sugita Y, Mattei MG, Chu ML, Knowlton R, Uitto J (March 1991). “Bullous pemphigoid antigen (BPAG1): cDNA cloning and mapping of the gene to the short arm of human chromosome 6”. Genomics8 (4): 722-726. doi:10.1016/0888-7543(90)90261-R. PMID 2276744.
^ abBrown A, Bernier G, Mathieu M, Rossant J, Kothary R (Jul 1995). “The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1”. Nat Genet10 (3): 301-306. PMID 7670468.
^Atai NA, Ryan SD, Kothary R, Breakefield XO, Nery FC (2012). “Untethering the nuclear envelope and cytoskeleton: biologically distinct dystonias arising from a common cellular dysfunction”. Int J Cell Biol2012: 18 pages. doi:10.1155/2012/634214. PMC: 3352338. PMID 22611399. http://www.hindawi.com/journals/ijcb/2012/634214/.
^Naldi L, Cazzaniga S, Borradori L (Aug 2012). “Bullous pemphigoid: simple measures for a complex disease”. J Invest Dermatol132 (8): 1948-1950. doi:10.1038/jid.2012.178. PMID 22797296. http://www.nature.com/jid/journal/v132/n8/full/jid2012178a.html.
^Bernier G, De Repentigny Y, Mathieu M, David S, Kothary R (Jun 1998). “Dystonin is an essential component of the Schwann cell cytoskeleton at the time of myelination”. Development125 (11): 2135-2148. PMID 9570777. http://dev.biologists.org/content/125/11/2135.long.
^Lifei Guo, Linda Degenstein, James Dowling, Qian-Chun Yu, Robert Wollmann, Benjamin Perman, Elaine Fuchs (Apr 1995). “Gene targeting of BPAG1: Abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration”. Cell81 (2): 233-243. doi:10.1016/0092-8674(95)90333-X. http://ac.els-cdn.com/009286749590333X/1-s2.0-009286749590333X-main.pdf?_tid=dbb22e2c-18fb-11e3-a780-00000aacb361&acdnat=1378695755_94edb5231991427b6ebd0194af33f1ee.
参考文献
清水宏 (April 2011). 新しい皮膚科学 (2 ed.). 東京: 中山書店. pp. 608. ISBN 1-4160-2999-0. http://www.derm-hokudai.jp/textbook/pdf/1-02.pdf2013年9月1日閲覧。.
Leighty L, Li N, Diaz LA, Liu Z (Nov 2007). “Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid”. Arch Dermatol Res299 (9): 417-422. PMID 17879094. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2064945/.
Green KJ, Jones JC (1996). “Desmosomes and hemidesmosomes: structure and function of molecular components”. FASEB J10 (8): 871-881. PMID 8666164.
Ferrier A, Boyer JG, Kothary R (2013). “Cellular and molecular biology of neuronal dystonin”. Int Rev Cell Mol Biol300: 85-120. doi:10.1016/B978-0-12-405210-9.00003-5.. PMID 23273860.
Alberts, Bruce; Johnson, Alexander; Lewis, Julian; Raff, Martin; Roberts, Keith; Walter, Peter (2002). “Cell Junctions”. Molecular Biology of the Cell (4th ed.). New York: Garland Science. ISBN 0-8153-3218-1. http://www.ncbi.nlm.nih.gov/books/NBK26867/.
関連項目
半接着斑(ヘミデスモソーム)
細胞接着分子
List of keratins expressed in the human integumentary system(英語)
List of target antigens in pemphigus(英語)
List of immunofluorescence findings for autoimmune bullous conditions(英語)
List of cutaneous conditions(英語)
List of histologic stains that aid in diagnosis of cutaneous conditions(英語)
… intracellular location of BP230 likely limits access of BP230 antibodies to the antigen. Nevertheless, in our experience, there is a subset of pemphigoid patients with increased BP230 antibody levels and normal …
…with BP230 (specifically, fused antigenic targets from the N-terminal domain, central rod domain, and C-terminal domain of human BP230 and which also is known as bullous pemphigoid antigen 1 [BPAg1]). …
…reveals reactivity with multiple antigens, including desmoplakins, desmogleins, and bullous pemphigoid antigen 1 (BPAg1, BP230) . Examples of generalized blistering disorders that are not necessarily associated…
…beneficial effects of IVIG on bullous pemphigoid are supported by evidence that serum levels of BP180 and BP230 antibodies decline in response to treatment. In an uncontrolled study of 10 patients with BP, treatment …
…immunofluorescence and serologic test for antibodies against the basement membrane antigens BP180 and BP230. Scabies – Scabies can mimic urticarial dermatitis clinically and histologically. Clinical findings…
English Journal
Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.
Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA.
The Journal of investigative dermatology. 2019 Sep;139(9)1860-1866.e1.
Bullous pemphigoid (BP) is an autoantibody-mediated blistering disease that is often associated with neurologic disease. BP antibodies target two epidermal adhesion molecules, known as BP180 and BP230. Homologues to these proteins are found in the brain, and it is hypothesized that neurologic diseas
BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.
Ali OH, Bomze D, Ring S, Berner F, Fässler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik CD, Flatz L.
Journal of the American Academy of Dermatology. 2019 Aug;().
Anti-PD1/PD-L1 therapy frequently entails immune-related adverse events (irAEs) and biomarkers to predict irAEs are lacking. While checkpoint inhibitors have been found to re-invigorate T-cells, the relevance of autoantibodies remains elusive. Our aim was to explore whether IgG autoantibodies direct